Q1 updated the commercial trajectory relative to Q4’s outlook: Q4 guidance was "$825 million to $850 million" for 2026 U.S. BRIUMVI net revenue, while Q1 said, "we're raising full year U.S. revenue ...
TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to ...
The OM System TG-7 is pretty much the same camera as the TG-6, which itself isn't very different than the TG-5. This relative lack of change is an effect of a shrinking compact camera market and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results